CGT6297
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA Mutations
Conditions
PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer
Trial Timeline
Feb 1, 2026 → Aug 1, 2029
NCT ID
NCT07383506About CGT6297
CGT6297 is a phase 1 stage product being developed by Cogent Biosciences for PIK3CA Mutations. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07383506. Target conditions include PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07383506 | Phase 1 | Recruiting |
Competing Products
13 competing products in PIK3CA Mutations
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib + Placebo | Novartis | Phase 2 | 52 |
| alpelisib | Novartis | Pre-clinical | 23 |
| BYL719 + Fulvestrant | Novartis | Phase 1 | 33 |
| BYL719 + AMG 479 | Novartis | Phase 1/2 | 41 |
| Inavolisib + Atezolizumab + Pembrolizumab | Roche | Phase 1 | 33 |
| RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | Relay Therapeutics | Phase 1 | 28 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 47 |
| RLY-2608 + Capivasertib + Fulvestrant | Relay Therapeutics | Phase 3 | 72 |
| RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg | Relay Therapeutics | Phase 1 | 28 |